Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) EBT (2016 - 2025)

Voyager Therapeutics' EBT history spans 11 years, with the latest figure at -$27.4 million for Q4 2025.

  • For Q4 2025, EBT rose 19.13% year-over-year to -$27.4 million; the TTM value through Dec 2025 reached -$119.6 million, down 85.86%, while the annual FY2025 figure was -$119.6 million, 85.86% down from the prior year.
  • EBT for Q4 2025 was -$27.4 million at Voyager Therapeutics, up from -$27.8 million in the prior quarter.
  • Across five years, EBT topped out at $124.7 million in Q1 2023 and bottomed at -$33.9 million in Q4 2024.
  • The 5-year median for EBT is -$22.9 million (2022), against an average of -$8.5 million.
  • The largest annual shift saw EBT tumbled 566.69% in 2022 before it soared 685.15% in 2023.
  • A 5-year view of EBT shows it stood at $5.1 million in 2021, then crashed by 566.69% to -$23.6 million in 2022, then surged by 342.34% to $57.2 million in 2023, then crashed by 159.25% to -$33.9 million in 2024, then grew by 19.13% to -$27.4 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's EBT are -$27.4 million (Q4 2025), -$27.8 million (Q3 2025), and -$33.4 million (Q2 2025).